135 related articles for article (PubMed ID: 15933064)
1. The interleukin-10 gene promoter polymorphism (-1082) does not correlate with clinical outcome in diffuse large B-cell lymphoma.
Berglund M; Thunberg U; Roos G; Rosenquist R; Enblad G
Blood; 2005 Jun; 105(12):4894-5; author reply 4895. PubMed ID: 15933064
[No Abstract] [Full Text] [Related]
2. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma.
Lech-Maranda E; Baseggio L; Bienvenu J; Charlot C; Berger F; Rigal D; Warzocha K; Coiffier B; Salles G
Blood; 2004 May; 103(9):3529-34. PubMed ID: 14701701
[TBL] [Abstract][Full Text] [Related]
3. The interleukin-10 gene promoter polymorphism -1087AG does not correlate with clinical outcome in non-Hodgkin's lymphoma.
Kube D; Hua TD; Klöss M; Kulle B; Brockmöller J; Wojnowski L; Löffler M; Pfreundschuh M; Trümper L
Genes Immun; 2007 Mar; 8(2):164-7. PubMed ID: 17215862
[TBL] [Abstract][Full Text] [Related]
4. Genetic association of interleukin-10 promoter polymorphisms and susceptibility to diffuse large B-cell lymphoma: a meta-analysis.
Cao HY; Zou P; Zhou H
Gene; 2013 May; 519(2):288-94. PubMed ID: 23485354
[TBL] [Abstract][Full Text] [Related]
5. No racial difference in allele frequencies of FCGR3A gene F158V polymorphisms in diffuse large B-cell lymphoma.
Hirakawa T; Yamaguchi H; Mitamura Y; Kosaka F; Dan K; Inokuchi K
Eur J Haematol; 2011 Feb; 86(2):180-1. PubMed ID: 21091537
[No Abstract] [Full Text] [Related]
6. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.
Kim DH; Jung HD; Kim JG; Lee JJ; Yang DH; Park YH; Do YR; Shin HJ; Kim MK; Hyun MS; Sohn SK
Blood; 2006 Oct; 108(8):2720-5. PubMed ID: 16609067
[TBL] [Abstract][Full Text] [Related]
7. [Application of gene expression profiling in molecular classification, prognosis and therapy of B-cell lymphoma].
Mao ZR; Zhou R; Zhang XX; Mueller-Hermelink Hk; Rosenwald A
Zhonghua Bing Li Xue Za Zhi; 2009 Nov; 38(11):785-9. PubMed ID: 20079025
[No Abstract] [Full Text] [Related]
8. Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma.
Giachelia M; Voso MT; Tisi MC; Martini M; Bozzoli V; Massini G; D'Aló F; Larocca LM; Leone G; Hohaus S
Leuk Lymphoma; 2012 Mar; 53(3):411-6. PubMed ID: 21902578
[TBL] [Abstract][Full Text] [Related]
9. The BCL-2 biomarker in the era of molecular diagnosis of diffuse large B-cell lymphoma.
Dunleavy K; Staudt LM; Wilson WH
Leuk Lymphoma; 2007 Jun; 48(6):1061-3. PubMed ID: 17577765
[No Abstract] [Full Text] [Related]
10. H2AFX polymorphisms are associated with decreased risk of diffuse large B cell lymphoma in Koreans.
Jin XM; Kim HN; Shin MH; Lee IK; Lee JS; Lee JH; Kim HJ; Choi JS; Juhng SW; Choi C
DNA Cell Biol; 2011 Dec; 30(12):1039-44. PubMed ID: 21631283
[TBL] [Abstract][Full Text] [Related]
11. The magic of microarrays.
Friend SH; Stoughton RB
Sci Am; 2002 Feb; 286(2):44-9, 53. PubMed ID: 11828700
[No Abstract] [Full Text] [Related]
12. Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab.
Yri OE; Ekstrøm PO; Hilden V; Gaudernack G; Liestøl K; Smeland EB; Holte H
Leuk Lymphoma; 2013 Oct; 54(10):2205-14. PubMed ID: 23391141
[TBL] [Abstract][Full Text] [Related]
13. Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma.
Hiraga J; Kinoshita T; Ohno T; Mori N; Ohashi H; Fukami S; Noda A; Ichikawa A; Naoe T
Int J Hematol; 2006 Oct; 84(3):248-55. PubMed ID: 17050200
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of the lamin A/C gene by CpG island promoter hypermethylation in hematologic malignancies, and its association with poor survival in nodal diffuse large B-cell lymphoma.
Agrelo R; Setien F; Espada J; Artiga MJ; Rodriguez M; Pérez-Rosado A; Sanchez-Aguilera A; Fraga MF; Piris MA; Esteller M
J Clin Oncol; 2005 Jun; 23(17):3940-7. PubMed ID: 15867203
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-10 - 1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection.
Persico M; Capasso M; Persico E; Masarone M; Renzo Ad; Spano D; Bruno S; Iolascon A
J Hepatol; 2006 Dec; 45(6):779-85. PubMed ID: 17049666
[TBL] [Abstract][Full Text] [Related]
16. Diffuse large B-cell lymphoma with overexpression of cyclin e substantiates poor standard treatment response and inferior outcome.
Tzankov A; Gschwendtner A; Augustin F; Fiegl M; Obermann EC; Dirnhofer S; Went P
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2125-32. PubMed ID: 16609025
[TBL] [Abstract][Full Text] [Related]
17. Primary mediastinal large B-cell lymphoma.
Savage KJ
Oncologist; 2006 May; 11(5):488-95. PubMed ID: 16720849
[TBL] [Abstract][Full Text] [Related]
18. Frequent DNA methylation but not mutation of the ID4 gene in malignant lymphoma.
Hagiwara K; Nagai H; Li Y; Ohashi H; Hotta T; Saito H
J Clin Exp Hematop; 2007 Apr; 47(1):15-8. PubMed ID: 17510533
[TBL] [Abstract][Full Text] [Related]
19. CD38 and interleukin 6 gene polymorphism in egyptians with diffuse large B-cell lymphoma (DLBCL).
Talaat RM; Abdel-Aziz AM; El-Maadawy EA; Abdel-Bary N
Immunol Invest; 2015; 44(3):265-78. PubMed ID: 25564959
[TBL] [Abstract][Full Text] [Related]
20. Impact of SNPs/Haplotypes of
Marangon AV; Colli CM; Cardozo DM; Visentainer JEL; Sell AM; Guimaraes F; Marques SBD; Lieber SR; Aranha FJP; Zulli R; de Souza VH; de Souza CA
J Immunol Res; 2019; 2019():2137538. PubMed ID: 31886296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
